Physician
Newton-Wellesley Hospital
Newton-Wellesley Hospital was paid $36.31M by Medicaid between Jan 2018 and Dec 2024, across 357 billing codes. Its largest line is 96361, Intravenous infusion, hydration; each additional hour — 14% of everything it billed.
33Billing provider infoNEWTON-WELLESLEY HOSPITAL
NEWTON, MA 02462
NEWTON, MA 02462
33aNPI1992737761assigned 07/06/2006
33bProvider typeFamily Medicine Physician
28Total paid$36.31M
24GClaims1,246,184
24DCodes billed357
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Family Medicine Physician providers in Massachusetts
Rank by total paid#1 of 744
Median peer was paid$10K
This provider vs. median3,470×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 144,958 | $3.92M | |
| 2019 | 147,887 | $4.12M | |
| 2020 | 139,043 | $3.75M | |
| 2021 | 199,480 | $5.73M | |
| 2022 | 224,784 | $7.04M | |
| 2023 | 216,263 | $5.61M | |
| 2024incomplete | 173,769 | $6.14M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 96361 | Intravenous infusion, hydration; each additional hour | 14% | 13,867 | 12,419 | $5.09M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 13% | 33,444 | 30,844 | $4.60M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 29,782 | 27,594 | $4.52M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.6% | 14,044 | 13,072 | $2.40M |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 3.4% | 9,404 | 8,273 | $1.23M |
| G0378 | Hospital observation service, per hour | 2.5% | 9,212 | 6,746 | $895K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.4% | 7,595 | 7,170 | $866K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2.1% | 5,756 | 5,312 | $775K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.1% | 13,208 | 11,839 | $761K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 2.0% | 5,908 | 5,428 | $743K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.9% | 6,820 | 6,372 | $692K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.7% | 5,013 | 4,720 | $627K |
345 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.6% | 4,232 | $568K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.5% | 4,303 | $549K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.5% | 10,777 | $529K |
| S9485 | Crisis intervention mental health services, per diem | 1.3% | 829 | $490K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,995 | $340K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 9,202 | $321K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 4,788 | $308K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 555 | $302K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 9,129 | $286K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 70,055 | $270K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 7,123 | $237K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 11,463 | $232K |
| 87631 | <1% | 2,416 | $224K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,653 | $206K |
| 76830 | Ultrasound, transvaginal | <1% | 2,793 | $202K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 14,805 | $202K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,347 | $190K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 10,584 | $181K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,231 | $168K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,188 | $165K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 6,601 | $163K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 17,700 | $163K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 6,442 | $156K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 20,812 | $154K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,163 | $143K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 1,539 | $142K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 147 | $137K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 702 | $136K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,669 | $131K |
| 59025 | Fetal non-stress test | <1% | 678 | $130K |
| J3490 | Unclassified drugs | <1% | 8,528 | $129K |
| ATP15 | <1% | 16,097 | $129K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 5,111 | $123K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 63,869 | $121K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 109 | $115K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 6,511 | $113K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 10,826 | $112K |
| 93971 | <1% | 1,074 | $108K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 1,286 | $103K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 134 | $101K |
| 84484 | <1% | 13,148 | $100K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 1,984 | $99K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 6,656 | $92K |
| 76770 | <1% | 707 | $92K | |
| 83880 | <1% | 5,818 | $91K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 744 | $90K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 256 | $90K |
| 83690 | <1% | 19,437 | $80K | |
| 87070 | <1% | 12,099 | $76K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 4,954 | $76K |
| 76642 | <1% | 896 | $74K | |
| 70496 | <1% | 523 | $72K | |
| 93308 | <1% | 449 | $71K | |
| 85027 | <1% | 22,810 | $70K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 16,461 | $68K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,077 | $67K |
| ATP08 | <1% | 12,724 | $66K | |
| 84702 | <1% | 5,673 | $65K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 4,791 | $64K |
| 83735 | <1% | 19,179 | $63K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 2,926 | $61K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,819 | $60K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 2,970 | $60K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,211 | $59K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 5,200 | $56K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 12,585 | $56K |
| 97161 | <1% | 1,264 | $55K | |
| 81001 | <1% | 31,517 | $55K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 209 | $54K |
| 81025 | <1% | 10,388 | $54K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 6,813 | $53K |
| 0002A | <1% | 1,478 | $49K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,108 | $48K |
| 0001A | <1% | 1,569 | $48K | |
| 82728 | <1% | 7,129 | $47K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 284 | $46K |
| 81513 | <1% | 673 | $45K | |
| 80050 | General health panel | <1% | 3,264 | $45K |
| 71045 | Radiologic examination, chest; single view | <1% | 6,284 | $43K |
| ATP14 | <1% | 8,432 | $42K | |
| 80076 | <1% | 37,271 | $38K | |
| 83605 | <1% | 5,659 | $38K | |
| 86803 | <1% | 4,414 | $38K | |
| 87040 | <1% | 3,930 | $37K | |
| ATP17 | <1% | 7,200 | $37K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 735 | $37K |
| 82607 | <1% | 5,752 | $36K | |
| 80053 | Comprehensive metabolic panel | <1% | 25,925 | $36K |
| 73502 | <1% | 1,320 | $35K | |
| 87660 | <1% | 2,237 | $35K | |
| 97803 | <1% | 504 | $34K | |
| 97162 | <1% | 800 | $34K | |
| 86140 | <1% | 10,484 | $33K | |
| 83970 | <1% | 2,129 | $33K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 24,719 | $28K |
| 83550 | <1% | 6,756 | $28K | |
| 72100 | <1% | 1,945 | $27K | |
| 86618 | <1% | 1,378 | $27K | |
| 87077 | <1% | 6,085 | $27K | |
| 85610 | <1% | 13,172 | $26K | |
| 86850 | <1% | 3,588 | $25K | |
| 87186 | <1% | 5,413 | $24K | |
| 87480 | <1% | 1,504 | $23K | |
| 87510 | <1% | 1,505 | $23K | |
| 86780 | <1% | 2,470 | $23K | |
| 83540 | <1% | 7,234 | $23K | |
| 73562 | <1% | 1,591 | $22K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,687 | $22K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 912 | $22K |
| 80061 | Lipid panel | <1% | 20,999 | $22K |
| 84439 | <1% | 5,285 | $22K | |
| 76536 | <1% | 258 | $22K | |
| 73630 | <1% | 1,653 | $22K | |
| 71250 | <1% | 568 | $22K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,396 | $22K |
| 86481 | <1% | 368 | $21K | |
| 73610 | <1% | 1,474 | $21K | |
| 85379 | <1% | 3,467 | $20K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 596 | $20K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 7,684 | $20K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 473 | $20K |
| 93975 | <1% | 288 | $20K | |
| 84153 | <1% | 2,076 | $19K | |
| 77065 | Tomosynthesis, mammo | <1% | 522 | $18K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 94 | $18K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 837 | $18K |
| 93017 | <1% | 289 | $18K | |
| ATP16 | <1% | 2,385 | $18K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 13,089 | $17K |
| 82784 | <1% | 2,108 | $17K | |
| ATP03 | <1% | 4,092 | $16K | |
| 85652 | <1% | 10,269 | $15K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 66 | $15K |
| 73030 | <1% | 1,164 | $15K | |
| 77080 | <1% | 324 | $14K | |
| 82746 | <1% | 2,241 | $14K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 535 | $13K |
| 20553 | <1% | 75 | $13K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 12,637 | $13K |
| 76801 | <1% | 139 | $13K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,011 | $13K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 708 | $12K |
| 87481 | <1% | 685 | $12K | |
| 73130 | <1% | 852 | $11K | |
| 93976 | <1% | 87 | $11K | |
| 82570 | <1% | 5,533 | $11K | |
| 87340 | <1% | 1,608 | $11K | |
| 74183 | <1% | 69 | $11K | |
| 74018 | <1% | 509 | $10K | |
| 84403 | <1% | 654 | $10K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 13,406 | $10K |
| J9999 | Not otherwise classified, antineoplastic drugs | <1% | 274 | $10K |
| ATP18 | <1% | 1,852 | $9K | |
| 82803 | <1% | 527 | $9K | |
| J2704 | Injection, propofol, 10 mg | <1% | 7,837 | $9K |
| ATP11 | <1% | 1,852 | $8K | |
| 83516 | <1% | 952 | $8K | |
| 97165 | <1% | 179 | $8K | |
| 82043 | <1% | 4,236 | $8K | |
| 84146 | <1% | 709 | $8K | |
| 73564 | <1% | 379 | $8K | |
| 74019 | <1% | 823 | $8K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,629 | $8K |
| 62323 | <1% | 18 | $8K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 6,864 | $7K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 7,936 | $7K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,384 | $7K |
| 84480 | <1% | 1,122 | $7K | |
| 86900 | <1% | 3,595 | $7K | |
| 86901 | <1% | 3,598 | $7K | |
| 96415 | <1% | 51 | $6K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,062 | $6K |
| 77066 | Tomosynthesis, mammo | <1% | 183 | $6K |
| 90715 | <1% | 342 | $6K | |
| 85007 | <1% | 3,178 | $6K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,734 | $6K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,661 | $6K |
| 90686 | <1% | 444 | $6K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 3,448 | $5K |
| 85730 | <1% | 1,187 | $5K | |
| ATP09 | <1% | 995 | $5K | |
| 97116 | <1% | 179 | $5K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 51 | $5K |
| 83001 | <1% | 421 | $5K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,268 | $5K |
| 86038 | <1% | 648 | $4K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 46 | $4K |
| 84100 | <1% | 7,459 | $4K | |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 27 | $4K |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 1,194 | $4K |
| 73110 | <1% | 357 | $4K | |
| 86762 | <1% | 395 | $4K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 3,168 | $4K |
| ATP07 | <1% | 798 | $4K | |
| 87205 | <1% | 1,648 | $4K | |
| 83883 | <1% | 436 | $4K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 33,614 | $4K |
| 86706 | <1% | 479 | $3K | |
| 87046 | <1% | 232 | $3K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 164 | $3K |
| 84425 | <1% | 257 | $3K | |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 51 | $3K |
| 81003 | <1% | 2,335 | $3K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,159 | $3K |
| 77062 | <1% | 24 | $3K | |
| 80164 | <1% | 846 | $3K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,443 | $2K |
| 0004A | <1% | 64 | $2K | |
| 82670 | <1% | 134 | $2K | |
| 97802 | <1% | 24 | $2K | |
| 80179 | <1% | 190 | $2K | |
| 20610 | <1% | 14 | $2K | |
| 88307 | <1% | 30 | $2K | |
| 82550 | <1% | 2,865 | $2K | |
| 87427 | <1% | 246 | $2K | |
| 84156 | <1% | 1,170 | $2K | |
| 76870 | <1% | 40 | $2K | |
| ATP10 | <1% | 460 | $2K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 15 | $2K |
| 70498 | <1% | 481 | $2K | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 864 | $2K |
| 84145 | <1% | 2,189 | $2K | |
| 84165 | <1% | 384 | $1K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 416 | $1K |
| ATP04 | <1% | 296 | $1K | |
| 87045 | <1% | 231 | $1K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 393 | $1K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 178 | $1K |
| 82150 | <1% | 420 | $1K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 54 | $1K |
| 87641 | <1% | 97 | $1K | |
| 70486 | <1% | 77 | $1K | |
| 73140 | <1% | 110 | $1K | |
| ATP02 | <1% | 401 | $1K | |
| 88304 | <1% | 290 | $1K | |
| 88342 | <1% | 283 | $1K | |
| 83002 | <1% | 92 | $1K | |
| 84550 | <1% | 1,977 | $1K | |
| 76882 | <1% | 13 | $1K | |
| J7999 | Compounded drug, not otherwise classified | <1% | 197 | $1K |
| 86141 | <1% | 169 | $1K | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 931 | $1K |
| 73560 | <1% | 150 | $1K | |
| 84402 | <1% | 50 | $1K | |
| 72170 | <1% | 87 | $1K | |
| 80299 | <1% | 65 | $969.96 | |
| 87807 | <1% | 103 | $952.52 | |
| 87501 | <1% | 27 | $950.46 | |
| 87640 | <1% | 96 | $908.75 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 482 | $852.84 |
| 83615 | <1% | 1,729 | $850.63 | |
| 82378 | <1% | 129 | $841.68 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 212 | $763.52 |
| 86769 | <1% | 31 | $758.34 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 40 | $722.82 |
| 80178 | <1% | 285 | $655.07 | |
| 87081 | <1% | 166 | $653.61 | |
| 83020 | <1% | 56 | $600.34 | |
| 86308 | <1% | 161 | $595.08 | |
| 0031A | <1% | 31 | $567.80 | |
| 81002 | <1% | 677 | $542.73 | |
| 86431 | <1% | 167 | $522.95 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 235 | $493.41 |
| 93298 | <1% | 38 | $491.30 | |
| 80143 | <1% | 79 | $460.32 | |
| 0064A | <1% | 12 | $458.70 | |
| 87449 | <1% | 70 | $399.99 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 248 | $387.36 |
| 87209 | <1% | 30 | $348.92 | |
| 84460 | <1% | 799 | $345.27 | |
| 83521 | <1% | 12 | $343.33 | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 1,642 | $328.74 |
| 73080 | <1% | 31 | $315.19 | |
| 71271 | <1% | 12 | $310.72 | |
| 87324 | <1% | 56 | $294.29 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 346 | $282.58 |
| 86765 | <1% | 30 | $279.09 | |
| 87338 | <1% | 25 | $278.96 | |
| 82533 | <1% | 49 | $267.66 | |
| 85045 | <1% | 133 | $265.12 | |
| 72040 | <1% | 44 | $241.94 | |
| 86677 | <1% | 28 | $237.09 | |
| 82962 | <1% | 2,999 | $202.26 | |
| 86704 | <1% | 27 | $180.71 | |
| 87177 | <1% | 30 | $172.70 | |
| 73590 | <1% | 30 | $172.18 | |
| 82040 | <1% | 552 | $163.47 | |
| 82565 | <1% | 523 | $154.53 | |
| 86787 | <1% | 12 | $152.75 | |
| 82950 | <1% | 65 | $152.66 | |
| 86235 | <1% | 12 | $147.24 | |
| 83993 | <1% | 13 | $138.48 | |
| 87207 | <1% | 25 | $120.34 | |
| 86334 | <1% | 47 | $115.20 | |
| 96376 | <1% | 1,801 | $114.71 | |
| 93296 | <1% | 12 | $109.88 | |
| 83721 | <1% | 27 | $104.40 | |
| 84450 | <1% | 782 | $100.08 | |
| 86376 | <1% | 12 | $92.89 | |
| 83921 | <1% | 13 | $84.80 | |
| 94664 | <1% | 39 | $82.12 | |
| 73660 | <1% | 12 | $78.83 | |
| 82248 | <1% | 542 | $77.65 | |
| 82947 | <1% | 79 | $62.74 | |
| 74175 | <1% | 14 | $40.12 | |
| 82977 | <1% | 26 | $25.62 | |
| Q3014 | Telehealth originating site facility fee | <1% | 57 | $17.52 |
| 82310 | <1% | 12 | $10.66 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 27 | $4.40 |
| 99152 | 0% | 419 | $0.00 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 2,445 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 181 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 66 | $0.00 |
| S0028 | Injection, famotidine, 20 mg | 0% | 188 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 151 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 260 | $0.00 |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | 0% | 60 | $0.00 |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | 0% | 16 | $0.00 |
| 91300 | 0% | 1,900 | $0.00 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 1,358 | $0.00 |
| 84155 | 0% | 26 | $0.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 13 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 13 | $0.00 |
| 77061 | 0% | 13 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 20 | $0.00 |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 0% | 12 | $0.00 |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | 0% | 15 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 3,229 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 814 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 961 | $0.00 |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | 0% | 264 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 23 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 42 | $0.00 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | 0% | 130 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 49 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 62 | $0.00 |
| 80320 | 0% | 300 | $0.00 | |
| 80069 | 0% | 43 | $0.00 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | 0% | 28 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 85 | $0.00 |
| C1769 | Guide wire | 0% | 13 | $0.00 |
| 80329 | 0% | 20 | $0.00 | |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 14 | $0.00 |
| 73090 | 0% | 12 | $0.00 | |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 21 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMCDERMOTT, VINCENT (SENIOR VP OF FINANCE/CFO)
| Provider | Location | Paid |
|---|---|---|
| Martha's Vineyard Hospital, INC. | Oak Bluffs, MA | $50.35M |
| Mass General Brigham Medical Group, INC. | Salem, NH | $758K |
| Martha's Vineyard Hospital, INC. | Oak Bluffs, MA | $94K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.